Latest Period
Q2 2026
Security Snapshot
Cartesian Therapeutics, Inc. - COMMON-STOCK (RNAC) Institutional Ownership
CUSIP: 816212302
13F Institutional Holders and Ownership History from Q1 2023 to Q2 2026
Institutions Reporting
54
Shares (Excl. Options)
2,927,880
Price
$10.42
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / COMMON-STOCK
- Symbol
- RNAC on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 2,927,880
- Total 13F value
- $30,483,420
- Portfolio coverage rank
- 0%
- Share change
- -84,013
- Value change
- -$705,212
- Number of holders
- 54
- Shares outstanding
- 29,387,746
- SEC-reported price per share
- $9.46
- Insider filing price
- $9.46
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- RNAC - Cartesian Therapeutics, Inc. - COMMON-STOCK is tracked under CUSIP 816212302.
- 54 institutions reported positions in Q2 2026.
- 6 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 81 to 54 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $43,929,103 to $30,483,420.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 54 institutions filings for Q2 2026.
Security key
816212302
Latest holder period
Q2 2026
13F holders
54
13D/G owners
6
CIK / CUSIP context first
Open Q2 2026 holders
RNAC full holder history
Cartesian Therapeutics, Inc. SEC filings
Cartesian Therapeutics, Inc. company facts
Cartesian Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 816212302:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
6
Security
RNAC
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| SPRINGER TIMOTHY A | 37% | +0.27% | $116,671,361 | +$258,583 | 9,555,394 | +0.22% | Timothy A. Springer | 13 Jan 2025 |
| Kalayoglu Murat | 20% | $48,188,600 | 5,833,971 | Murat Kalayoglu | 31 Mar 2026 | |||
| Squarepoint Ops LLC | 8.3% | $14,163,542 | 2,209,601 | Squarepoint Ops LLC | 09 Mar 2026 | |||
| BARCLAYS PLC | 6% | $16,652,684 | 1,760,326 | Barclays PLC | 30 Jun 2026 | |||
| JPMORGAN CHASE & CO | 4.8% | -22% | $15,486,449 | -$1,973,343 | 1,486,252 | -11% | JPMORGAN CHASE & CO. | 30 Jun 2026 |
| FMR LLC | 3% | -46% | $4,990,396 | -$3,539,615 | 799,743 | -41% | FMR LLC | 31 Mar 2026 |
As of 30 Jun 2026, 54 institutional investors reported holding 2,927,880 shares of Cartesian Therapeutics, Inc. - COMMON-STOCK (RNAC). This represents 10% of the company’s total 29,387,746 outstanding shares.
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
14
Latest
Q2 2026
Rows shown
1-14 of 14
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 2,927,880 | $30,483,420 | -$705,212 | $10.42 | 54 |
| 2026 Q1 | 7,151,630 | $43,929,103 | +$11,824,816 | $6.15 | 81 |
| 2025 Q4 | 5,161,870 | $37,214,593 | -$8,841,222 | $7.21 | 66 |
| 2025 Q3 | 5,968,086 | $60,898,831 | -$4,440,064 | $10.22 | 65 |
| 2025 Q2 | 6,401,037 | $66,468,780 | -$2,049,017 | $10.39 | 65 |
| 2025 Q1 | 6,582,077 | $86,710,172 | -$755,346 | $13.18 | 68 |
| 2024 Q4 | 6,665,799 | $119,478,509 | -$2,692,613 | $17.91 | 64 |
| 2024 Q3 | 6,867,968 | $110,349,366 | +$42,879,892 | $16.12 | 61 |
| 2024 Q2 | 3,268,033 | $88,276,427 | +$88,059,260 | $27.01 | 57 |
| 2024 Q1 | 1,855 | $1,157 | +$1,157 | $0.64 | 4 |
| 2023 Q4 | 0 | $0 | -$1,272 | $9.46 | 0 |
| 2023 Q3 | 1,200 | $1,272 | $1.06 | 1 | |
| 2023 Q2 | 1,200 | $1,344 | $1.12 | 1 | |
| 2023 Q1 | 1,200 | $1,668 | +$1,668 | $1.39 | 1 |